William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on SPRY stock, giving a Buy rating on November 11.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lachlan Hanbury Brown has given his Buy rating due to a combination of factors that highlight ARS Pharmaceuticals’ strategic positioning in the market. The recent data on Anaphylm’s safety and tolerability profile, despite showing a high rate of adverse events, underscores neffy’s differentiated profile, which is expected to capture a significant market opportunity even if Anaphylm gains approval. Neffy’s first-mover advantage and its robust efficacy data suggest a promising market potential, especially as it expands the epinephrine market beyond current autoinjector users.
Furthermore, ARS Pharmaceuticals has been successful in driving demand for neffy, which is anticipated to translate into increased prescriptions and revenue. The company’s commercial initiatives are gaining traction, and while there are still barriers to prescribing, efforts such as the ‘Get neffy on Us’ program and upcoming FDA workshops are expected to enhance access and coverage. With strong financial backing to support neffy’s launch, Lachlan Hanbury Brown sees blockbuster potential for the product, justifying the Buy rating.
According to TipRanks, Hanbury Brown is a 4-star analyst with an average return of 19.0% and a 60.00% success rate. Hanbury Brown covers the Healthcare sector, focusing on stocks such as ARS Pharmaceuticals, Harrow Health, and Ocular Therapeutix.
In another report released on November 11, Roth MKM also reiterated a Buy rating on the stock with a $30.00 price target.